克罗恩病纤维化的新生物标志物

Gianluca Pellino, Pierlorenzo Pallante, Francesco Selvaggi
{"title":"克罗恩病纤维化的新生物标志物","authors":"Gianluca Pellino,&nbsp;Pierlorenzo Pallante,&nbsp;Francesco Selvaggi","doi":"10.4291/wjgp.v7.i3.266","DOIUrl":null,"url":null,"abstract":"<p><p>Fibrosis represents a major challenge in Crohn's disease (CD), and many CD patients will develop fibrotic strictures requiring treatment throughout their lifetime. There is no drug that can reverse intestinal fibrosis, and so endoscopic balloon dilatation and surgery are the only effective treatments. Since patients may need repeated treatments, it is important to obtain the diagnosis at an early stage before strictures become symptomatic with extensive fibrosis. Several markers of fibrosis have been proposed, but most need further validation. Biomarkers can be measured either in biological samples obtained from the serum or bowel of CD patients, or using imaging tools and tests. The ideal tool should be easily obtained, cost-effective, and reliable. Even more challenging is fibrosis occurring in ulcerative colitis. Despite the important burden of intestinal fibrosis, including its detrimental effect on outcomes and quality of life in CD patients, it has received less attention than fibrosis occurring in other organs. A common mechanism that acts via a specific signaling pathway could underlie both intestinal fibrosis and cancer. A comprehensive overview of recently introduced biomarkers of fibrosis in CD is presented, along with a discussion of the controversial areas remaining in this field. </p>","PeriodicalId":23760,"journal":{"name":"World Journal of Gastrointestinal Pathophysiology","volume":"7 3","pages":"266-75"},"PeriodicalIF":0.0000,"publicationDate":"2016-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4981766/pdf/WJGP-7-266.pdf","citationCount":"17","resultStr":"{\"title\":\"Novel biomarkers of fibrosis in Crohn's disease.\",\"authors\":\"Gianluca Pellino,&nbsp;Pierlorenzo Pallante,&nbsp;Francesco Selvaggi\",\"doi\":\"10.4291/wjgp.v7.i3.266\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Fibrosis represents a major challenge in Crohn's disease (CD), and many CD patients will develop fibrotic strictures requiring treatment throughout their lifetime. There is no drug that can reverse intestinal fibrosis, and so endoscopic balloon dilatation and surgery are the only effective treatments. Since patients may need repeated treatments, it is important to obtain the diagnosis at an early stage before strictures become symptomatic with extensive fibrosis. Several markers of fibrosis have been proposed, but most need further validation. Biomarkers can be measured either in biological samples obtained from the serum or bowel of CD patients, or using imaging tools and tests. The ideal tool should be easily obtained, cost-effective, and reliable. Even more challenging is fibrosis occurring in ulcerative colitis. Despite the important burden of intestinal fibrosis, including its detrimental effect on outcomes and quality of life in CD patients, it has received less attention than fibrosis occurring in other organs. A common mechanism that acts via a specific signaling pathway could underlie both intestinal fibrosis and cancer. A comprehensive overview of recently introduced biomarkers of fibrosis in CD is presented, along with a discussion of the controversial areas remaining in this field. </p>\",\"PeriodicalId\":23760,\"journal\":{\"name\":\"World Journal of Gastrointestinal Pathophysiology\",\"volume\":\"7 3\",\"pages\":\"266-75\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-08-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4981766/pdf/WJGP-7-266.pdf\",\"citationCount\":\"17\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World Journal of Gastrointestinal Pathophysiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4291/wjgp.v7.i3.266\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Gastrointestinal Pathophysiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4291/wjgp.v7.i3.266","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 17

摘要

纤维化是克罗恩病(CD)的主要挑战,许多CD患者一生中都会出现纤维化狭窄,需要治疗。目前还没有药物可以逆转肠道纤维化,因此内窥镜球囊扩张和手术是唯一有效的治疗方法。由于患者可能需要反复治疗,在狭窄成为广泛纤维化的症状之前获得早期诊断是重要的。已经提出了几种纤维化标志物,但大多数需要进一步验证。生物标志物可以在从乳糜泻患者的血清或肠道中获得的生物样本中测量,也可以使用成像工具和测试。理想的工具应该容易获得,成本效益高,可靠。更具挑战性的是溃疡性结肠炎中发生的纤维化。尽管肠纤维化是重要的负担,包括其对CD患者预后和生活质量的不利影响,但与发生在其他器官的纤维化相比,它受到的关注较少。一种通过特定信号通路起作用的共同机制可能是肠道纤维化和癌症的基础。对最近介绍的CD纤维化生物标志物进行了全面概述,并对该领域仍存在争议的领域进行了讨论。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Novel biomarkers of fibrosis in Crohn's disease.

Fibrosis represents a major challenge in Crohn's disease (CD), and many CD patients will develop fibrotic strictures requiring treatment throughout their lifetime. There is no drug that can reverse intestinal fibrosis, and so endoscopic balloon dilatation and surgery are the only effective treatments. Since patients may need repeated treatments, it is important to obtain the diagnosis at an early stage before strictures become symptomatic with extensive fibrosis. Several markers of fibrosis have been proposed, but most need further validation. Biomarkers can be measured either in biological samples obtained from the serum or bowel of CD patients, or using imaging tools and tests. The ideal tool should be easily obtained, cost-effective, and reliable. Even more challenging is fibrosis occurring in ulcerative colitis. Despite the important burden of intestinal fibrosis, including its detrimental effect on outcomes and quality of life in CD patients, it has received less attention than fibrosis occurring in other organs. A common mechanism that acts via a specific signaling pathway could underlie both intestinal fibrosis and cancer. A comprehensive overview of recently introduced biomarkers of fibrosis in CD is presented, along with a discussion of the controversial areas remaining in this field.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtyping Sepsis during short bowel syndrome hospitalizations: Identifying trends, disparities, and clinical outcomes in the United States Des-gamma-carboxy prothrombin and alpha-fetoprotein levels as biomarkers for hepatocellular carcinoma and their correlation with radiological characteristics Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities Prevalence and outcome of sarcopenia in non-alcoholic fatty liver disease
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1